TY - JOUR
T1 - A novel automated endovascular variable aortic control device to expand function of standard reboa catheters
AU - Williams, Timothy K.
AU - Neff, Lucas P.
AU - Tibbits, Emily M.
AU - Hoareau, Guillaume L.
AU - Simon, Meryl A.
AU - Davidson, Anders J.
AU - Desoucy, Erik S.
AU - Faulconer, E. Robert
AU - Johnson, M. Austin
N1 - Funding Information:
Funding: Funding for this study was provided by the Clinical Investigation Facility, David Grant Medical Center, Travis Air Force Base, CA. Presentation: none. Disclosure: The views expressed in this material are those of the authors and do not reflect the official policy or position of the U.S. Government, the Department of Defense, the Department of the Air Force, or the University of California Davis. The animals involved in this study were procured, maintained, and used in accordance with the Laboratory Animal Welfare Act of 1966, as amended, and the Guide for the Care and Use of Laboratory Animals, National Research Council. The work reported herein was performed under United States Air Force Surgeon General-approved Clinical Investigation No. FDG20170005A. © 2019 CC BY 4.0 – in cooperation with Depts. of Cardiothoracic/Vascular Surgery, General Surgery and Anesthesia, Örebro University Hospital and Örebro University, Sweden Results: The EVAC syringe pump was highly effective at maintaining precise aortic flow throughout the 45-minute intervention period during steady-state conditions as well as during rapid fluid administration. Aortic flow and distal mean arterial pressure remained stable during EVAC, despite changing proximal hemodynamics. Balloon volume was dynamic, averaging over 500 changes during intervention, with a mean volume change of 6.7 μL and a maximal change of 100 μL. Conclusions: The EVAC syringe pump is capable of achieving aortic flow regulation with high precision, beyond what is achievable with manual control. This serves as a model for future device design, enabling as-of-yet unachievable clinical therapies for hemorrhage and shock states. Future technological development is required to fully translate this into clinical use.
PY - 2019
Y1 - 2019
N2 - Background: Endovascular methods for hemorrhage control, including resuscitative endovascular balloon occlusion of the aorta (REBOA), are evolving and are increasingly being applied clinically. Partial flow strategies to mitigate the consequences of complete aortic occlusion have been demonstrated in pre-clinical models to enhance REBOA and expand its application to various shock states. Initial studies demonstrated that controlled partial flow requires precision beyond the capabilities of manual balloon volume adjustment, therefore automation is required. Our group previously developed a proof-of-concept computer-controlled extracorporeal flow circuit capable of precision aortic flow regulation, but it was not clinically applicable. To bring this concept closer to clinical applicability, we have developed the first endovascular strategy to achieve precision aortic flow regulation, termed endovascular variable aortic control (EVAC). Methods: Following instrumentation, five Yorkshire-cross swine were subjected to controlled 25% hemorrhage, followed by precision low volume aortic flow regulation using a commercially available compliant balloon catheter pre-positioned in the descending thoracic aorta, connected to a custom, wireless syringe pump. Closed-loop feed-back algorithms based on streaming physiologic data were used to determine balloon volume changes. Results: The EVAC syringe pump was highly effective at maintaining precise aortic flow throughout the 45-minute intervention period during steady-state conditions as well as during rapid fluid administration. Aortic flow and distal mean arterial pressure remained stable during EVAC, despite changing proximal hemodynamics. Balloon volume was dynamic, averaging over 500 changes during intervention, with a mean volume change of 6.7 μL and a maximal change of 100 μL. Conclusions: The EVAC syringe pump is capable of achieving aortic flow regulation with high precision, beyond what is achievable with manual control. This serves as a model for future device design, enabling as-of-yet unachiev-able clinical therapies for hemorrhage and shock states. Future technological development is required to fully trans-late this into clinical use.
AB - Background: Endovascular methods for hemorrhage control, including resuscitative endovascular balloon occlusion of the aorta (REBOA), are evolving and are increasingly being applied clinically. Partial flow strategies to mitigate the consequences of complete aortic occlusion have been demonstrated in pre-clinical models to enhance REBOA and expand its application to various shock states. Initial studies demonstrated that controlled partial flow requires precision beyond the capabilities of manual balloon volume adjustment, therefore automation is required. Our group previously developed a proof-of-concept computer-controlled extracorporeal flow circuit capable of precision aortic flow regulation, but it was not clinically applicable. To bring this concept closer to clinical applicability, we have developed the first endovascular strategy to achieve precision aortic flow regulation, termed endovascular variable aortic control (EVAC). Methods: Following instrumentation, five Yorkshire-cross swine were subjected to controlled 25% hemorrhage, followed by precision low volume aortic flow regulation using a commercially available compliant balloon catheter pre-positioned in the descending thoracic aorta, connected to a custom, wireless syringe pump. Closed-loop feed-back algorithms based on streaming physiologic data were used to determine balloon volume changes. Results: The EVAC syringe pump was highly effective at maintaining precise aortic flow throughout the 45-minute intervention period during steady-state conditions as well as during rapid fluid administration. Aortic flow and distal mean arterial pressure remained stable during EVAC, despite changing proximal hemodynamics. Balloon volume was dynamic, averaging over 500 changes during intervention, with a mean volume change of 6.7 μL and a maximal change of 100 μL. Conclusions: The EVAC syringe pump is capable of achieving aortic flow regulation with high precision, beyond what is achievable with manual control. This serves as a model for future device design, enabling as-of-yet unachiev-able clinical therapies for hemorrhage and shock states. Future technological development is required to fully trans-late this into clinical use.
KW - Automation
KW - EVAC
KW - Hemorrhage
KW - P-REBOA
KW - REBOA
UR - http://www.scopus.com/inward/record.url?scp=85071127517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071127517&partnerID=8YFLogxK
U2 - 10.26676/jevtm.v3i1.65
DO - 10.26676/jevtm.v3i1.65
M3 - Article
AN - SCOPUS:85071127517
VL - 3
SP - 3
EP - 10
JO - Journal of Endovascular Resuscitation and Trauma Management
JF - Journal of Endovascular Resuscitation and Trauma Management
SN - 2002-7567
IS - 1
ER -